Adams Takes CEO Spot at Sepracor

PharmaManufacturing.com
05/15/2007

Sepracor Inc. announced May 15 that Adrian Adams, the company's president and chief operating officer, has been elected chief executive officer, effective immediately. Mr. Adams assumes the chief executive role from Timothy J. Barberich, who has been elected executive chairman of the Board of Directors.

"I am proud of all that we at Sepracor have accomplished over the last 23 years. I look forward to strong contributions from Adrian as he assumes leadership of the company," said Barberich. "I believe that his wealth of experience in the pharmaceutical industry, combined with his energy and vision, will be great assets in enabling Sepracor's future growth and success."

Adams joined Sepracor on March 1, 2007. Previously, he was president and CEO of Kos Pharmaceuticals, Inc. from 2002 until that company was acquired by Abbott Laboratories in December 2006. During his tenure, he increased revenues ten-fold and led the transformation of Kos into a fully integrated and profitable pharmaceutical company with annual revenues approaching one billion dollars and strong positions in the cardiovascular and respiratory disease areas. Adams has more than 30 years of experience in both specialty and large pharmaceutical organizations that, in addition to Kos, included careers with ICI, SmithKline Beecham and Novartis. His background encompasses research and development, sales, international and national product marketing, business development and extensive general management experience.